Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 16/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 16/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | CDC42 | P60953 | 1/20 | 0.58 |
| ▸ | RAC1 | P63000 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380164 | 1.00 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9116873 | 1.00 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9239300 | 0.88 | RXFP1 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL7772358 | 0.88 | PTGS2 (0.45) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9243634 | 0.88 | RXFP1 (0.44) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL10537008 | 0.88 | RXFP1 (0.47) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9868774 | 0.85 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9868769 | 0.85 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| SCHEMBL9868760 | 0.85 | AKR1C3 (0.43) | AKR1C3AKR1C2PTGS2PTGS1CDC42 | |
| Methoxymethane SCHEMBL10539889 | 0.84 | AKR1C3 (0.42) | AKR1C3AKR1C2PTGS2PTGS1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532098-A1 | PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN | Nicox S.A. (FR) | 2005-05-25 | — | — | EP | claimed |
| WO-2004020384-A1 | PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN | NICOX S.A. (FR) | 2004-03-11 | — | — | WO | claimed |
| US-5023365-A | Process for preparing an intermediate | ZAMBON GROUP S.P.A. (IT) | 1991-06-11 | — | — | US | claimed |
| EP-1532098-B1 | PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN | NICOX SA (FR) | 2009-11-18 | — | — | EP | disclosed |
| US-7199258-B2 | Process for preparing nitrooxyderivatives of naproxen | NICOX S.A. (FR) | 2007-04-03 | — | — | US | disclosed |
| US-20060173005-A1 | Process for preparing nitrooxyderivative of naproxen | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1532098-A1 | PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN | Nicox S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004020384-A1 | PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN | NICOX S.A. (FR) | 2004-03-11 | — | — | WO | disclosed |
| EP-0641304-A1 | STEREO-SELECTIVE SYNTHESIS OF 2-ARYL-PROPIONIC ACIDS OF HIGH OPTICAL PURITY BY USING CHIRAL OXAZOLINES | CHEMISCH BIOTECHNOLOGISCHE LABORATORIEN GMBH (DE) | 1995-03-08 | — | — | EP | disclosed |
| US-5380927-A | Process for preparing optically active 2-aryl-alkanoic acids, in particular 2-aryl-propionic acids | MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1995-01-10 | — | — | US | disclosed |
| US-5274186-A | Intermediates and their use in the synthesis of organic compounds | ZAMBON S.P.A. (IT) | 1993-12-28 | — | — | US | disclosed |
| US-4888433-A | CHIRAL HALOGENATED KETALS WHICH UNDERGO STEREOSELECTIVE REARRANGEMENT | ZAMBON, S.P.A. (IT) | 1989-12-19 | — | — | US | disclosed |
| US-4845243-A | Intermediates and their use in the synthesis of organic compounds | ZAMBON S.P.A. (IT) | 1989-07-04 | — | — | US | disclosed |
| US-4810819-A | STEREOSELECTIVE HALOGENATION AND REARRANGEMENT | ZAMBON SPA (IT) | 1989-03-07 | — | — | US | disclosed |
| EP-0158913-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND INTERMEDIATES THEREOF | ZAMBON S.p.A. (IT) | 1988-07-20 | — | — | EP | disclosed |
| EP-0272644-A2 | Intermediates and their use in the synthesis of organic compounds | ZAMBON S.p.A. (IT) | 1988-06-29 | — | — | EP | disclosed |
| EP-0254971-A1 | Carboxylic acid synthesis process | ZAMBON S.p.A. (IT) | 1988-02-03 | — | — | EP | disclosed |
| US-4697036-A | HALOGENATION, REARRANGEMENT | ZAMBON S.P.A. (IT) | 1987-09-29 | — | — | US | disclosed |
| EP-0110671-B1 | PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND PRECURSORS THEREOF | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1986-05-21 | — | — | EP | disclosed |
| EP-0158913-A2 | Process for the preparation of optically active alpha-arylalkanoic acids and intermediates thereof | ZAMBON S.p.A. (IT) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173005-A1 | Process for preparing nitrooxyderivative of naproxen | CYP2A13, POR, CYP3A43 | AKR1C3 409/4885AKR1C2 970/4885PTGS2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.